pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

191 catalysts · 45 phase 2 completion · 31 phase 1 completion · 24 phase 2 initiation · 21 phase 1 2 completion · 17 phase 1 initiation · 12 phase 1 2 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 1 catalyst2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: epilepsy×TA: pain×TA: oncology×TA: infectious-disease×clear all
type
  • phase 2 completion45
  • phase 1 completion31
  • phase 2 initiation24
  • phase 1 2 completion21
  • phase 1 initiation17
  • phase 1 2 initiation
12
  • patent expiry8
  • phase 0 trial completion6
  • phase 3 completion6
  • phase iv trial initiation4
  • therapy area
    • Oncology139
    • Infectious Disease41
    • Cardiology37
    • Immunology32
    • Dermatology27
    • Pulmonology19
    • Women's Health16
    • Ophthalmology15
    • Pain12

    Week of Apr 20, 2026

    24
    ›Apr 25, 2026constraining patent expiry europe90d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Europe))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026patent expiry90d agoStemline Therapeutics Inc — SL-901 (Constraining Patent Expiry (Japan))SL-901

    Therapy area: Oncology, Undisclosed. Indication: Lung Cancer, Solid Tumor, Unspecified Rare Disease

    full page →SL-901 →source: globaldata
    ›Apr 25, 2026phase 1 completion90d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

    Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

    full page →influenza (trivalent, split virion) vaccine →source: globaldata
    ›Apr 25, 2026phase 1 completion90d agoHenan Cancer Hospital — GH-2616 (Phase I Trial Completion)GH-2616

    Therapy area: Oncology. Indication: Lung Adenocarcinoma, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Solid Tumor, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Uterine Cancer

    full page →GH-2616 →source: globaldata
    ›Apr 25, 2026phase 1 2 completion90d agoGeneral Hospital of the People's Liberation Army — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Nodal Marginal Zone B-Cell Lymphoma, Non-Hodgkin Lymphoma, Primary Mediastinal B-Cell Lymphoma, Splenic Marginal Zone B-Cell Lymphoma

    full page →cyclophosphamide →source: globaldata
    ›Apr 25, 2026phase 1 2 completion90d agoShanghai YaKe Biotechnology Co Ltd — CD7 CAR-T Cells (Phase I/II Trial Completion)CD7 CAR-T Cells

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

    full page →CD7 CAR-T Cells →source: globaldata
    ›Apr 25, 2026phase 2 completion90d agoTianjin Medical University Cancer Institute and Hospital — fluorouracil (Phase II Trial Completion)Efudex

    Therapy area: Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma)

    full page →Efudex →source: globaldata
    ›Apr 25, 2026phase 2 completion90d agoTehran University of Medical Sciences — FOLFOX [leucovorin + fluorouracil + oxaliplatin] (Phase II Trial Completion)FOLFOX [leucovorin + fluorouracil + oxaliplatin]

    Therapy area: Oncology. Indication: Rectal Cancer

    full page →FOLFOX [leucovorin + fluorouracil + oxaliplatin] →source: globaldata
    ›Apr 25, 2026phase 2 completion90d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

    Therapy area: Infectious Disease. Indication: Dental Abscess

    full page →Gengigel →source: globaldata
    ›Apr 25, 2026phase 2 completion90d agoSoochow University Hospital 1 — blinatumomab (Phase II Trial Completion)blinatumomab

    Therapy area: Oncology. Indication: B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →blinatumomab →source: globaldata
    ›Apr 25, 2026phase 2 initiation90d agoAffiliated Hospital of North Sichuan Medical College — Radioactive Iodine Therapy (Phase II Trial Initiation)Radioactive Iodine Therapy

    Therapy area: Oncology. Indication: Follicular Thyroid Cancer, Papillary Thyroid Cancer, Thyroid Cancer

    full page →Radioactive Iodine Therapy →source: globaldata
    ›Apr 25, 2026phase 2 initiation90d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →dostarlimab →source: globaldata
    ›Apr 25, 2026phase 2 initiation90d agoShanghai Henlius Biotech Inc — HLX-43 (Phase II Trial Initiation)HLX-43

    Therapy area: Oncology. Indication: Breast Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

    full page →HLX-43 →source: globaldata
    ›Apr 25, 2026phase 2 initiation90d agoJazz Pharmaceuticals Plc — durvalumab (Phase II Trial Initiation)durvalumab

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →durvalumab →source: globaldata
    ›Apr 25, 2026phase 2 initiation90d agoNovartis AG — asciminib hydrochloride (Phase II Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 25, 2026phase iv trial initiation90d agoChristian Medical College Vellore — ketorolac (Phase IV Trial Initiation)ketorolac

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Pain, Renal Colic, Renal Stones/Calculi

    full page →ketorolac →source: globaldata
    ›Apr 26, 2026phase 1 completion89d agoPfizer Inc — PF-08046032 (Phase I Trial Completion)PF-08046032

    Therapy area: Oncology. Indication: Advanced Malignancy, Diffuse Large B-Cell Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Solid Tumor

    full page →PF-08046032 →source: globaldata
    ›Apr 26, 2026phase 2 completion89d agoAnyang Tumor Hospital — camrelizumab (Phase II Trial Completion)apatinib mesylate

    Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

    full page →apatinib mesylate →source: globaldata
    ›Apr 26, 2026phase 2 completion89d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

    full page →bupivacaine →source: globaldata
    ›Apr 26, 2026phase 2 completion89d agoMemorial Sloan Kettering Cancer Center — iberdomide hydrochloride (Phase II Trial Completion)iberdomide hydrochloride

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease)

    full page →iberdomide hydrochloride →source: globaldata
    ›Apr 26, 2026phase 2 initiation89d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 2 initiation89d agoBeijing StarMab BioMed Technology Ltd — SM-3321 (Phase II Trial Initiation)SM-3321

    Therapy area: Oncology. Indication: Advanced Malignancy, Solid Tumor

    full page →SM-3321 →source: globaldata
    ›Apr 26, 2026phase 2 results89d agoAllogene Therapeutics Inc — ALLO-647 (Phase II Trial Results)ALLO-647

    Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma

    full page →ALLO-647 →source: globaldata
    ›Apr 26, 2026phase 3 completion89d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

    Therapy area: Infectious Disease. Indication: Rabies

    full page →rabies vaccine →source: globaldata

    Week of Apr 27, 2026

    26
    ›Apr 27, 2026phase 1 initiation88d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

    full page →pembrolizumab →source: globaldata
    ›Apr 27, 2026constraining patent expiry europe
    ← prev
    page 1 of 4
    next →
    88d ago
    Bill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Europe))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026patent expiry88d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026phase 1 initiation88d agoCity of Hope — CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] (Phase I Trial Initiation)CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone]

    Therapy area: Oncology. Indication: Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Follicular Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), T-Cell Lymphomas

    full page →CHOP [cyclophosphamide + doxorubicin + vincristine + prednisolone] →source: globaldata
    ›Apr 27, 2026phase 1 initiation88d agoNational Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)Autologous B7-H3 CAR T

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Small-Cell Lung Cancer, Solid Tumor

    full page →Autologous B7-H3 CAR T →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation88d agoNational Institutes of Health Clinical Center — azacitidine (Phase I/II Trial Initiation)Onureg

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma

    full page →Onureg →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation88d agoThe National Institute of Diabetes and Digestive and Kidney Diseases — EBTATE (Phase I/II Trial Initiation)EBTATE

    Therapy area: Oncology. Indication: Thyroid Cancer

    full page →EBTATE →source: globaldata
    ›Apr 27, 2026phase 1 2 initiation88d agoNational Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)sacituzumab govitecan

    Therapy area: Oncology. Indication: Neuroendocrine Cancer, Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →sacituzumab govitecan →source: globaldata
    ›Apr 27, 2026phase 2 completion88d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 completion88d agoPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)nivolumab

    Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Squamous Non-Small Cell Lung Cancer

    full page →nivolumab →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoShanghai Henlius Biotech Inc — HLX-35 (Phase II Trial Initiation)HLX-35

    Therapy area: Oncology. Indication: Solid Tumor, Squamous Non-Small Cell Lung Cancer

    full page →HLX-35 →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoJiangsu Hengrui Pharmaceuticals Co Ltd — HRS-3738 (Phase II Trial Initiation)HRS-3738

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →HRS-3738 →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoYichun Maternal and Child health Care Hospital — sufentanil (Phase II Trial Initiation)sufentanil

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoWeifang Yidu Central Hospital — liposome bupivacaine (Phase II Trial Initiation)liposome bupivacaine

    Therapy area: Oncology. Indication: Lung Cancer

    full page →liposome bupivacaine →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoNational Cancer Institute US — busulfan (Phase II Trial Initiation)busulfan

    Therapy area: Oncology. Indication: Blood Cancer, Hematological Tumor, Leukemia, Lymphoma

    full page →busulfan →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoCentral South University Xiangya Hospital 3 — HRS-2129 (Phase II Trial Initiation)HRS-2129

    Therapy area: Central Nervous System. Indication: Pain

    full page →HRS-2129 →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

    Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

    full page →brincidofovir →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoJiangsu Hengrui Pharmaceuticals Co Ltd — fruquintinib (Phase II Trial Initiation)fruquintinib

    Therapy area: Oncology. Indication: Colorectal Cancer

    full page →fruquintinib →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoNational Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)cyclophosphamide

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

    full page →cyclophosphamide →source: globaldata
    ›Apr 27, 2026phase 2 initiation88d agoChongqing Cancer Hospital — ondansetron (Phase II Trial Initiation)ondansetron ODT

    Therapy area: Oncology. Indication: Ovarian Cancer

    full page →ondansetron ODT →source: globaldata
    ›Apr 27, 2026phase 2 3 completion88d agoAnthem Biosciences Ltd — berubicin hydrochloride (Phase II/III Trial Completion)berubicin hydrochloride

    Therapy area: Oncology. Indication: Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM)

    full page →berubicin hydrochloride →source: globaldata
    ›Apr 27, 2026phase 3 completion88d agoCellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)elranatamab

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →elranatamab →source: globaldata
    ›Apr 27, 2026phase 3 completion88d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

    Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

    full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata
    ›Apr 27, 2026phase iv trial initiation88d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

    Therapy area: Infectious Disease. Indication: Typhoid Fever

    full page →typhoid Vi polysaccharide vaccine →source: globaldata
    ›Apr 28, 2026constraining patent expiry europe87d agoLupin Ltd — (dolutegravir + lamivudine + tenofovir disoproxil fumarate) (Constraining Patent Expiry (Europe))(dolutegravir + lamivudine + tenofovir disoproxil fumarate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(dolutegravir + lamivudine + tenofovir disoproxil fumarate) →source: globaldata
    ›Apr 28, 2026patent expiry87d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    $GSK50.74-0.04%
    $PFE25.01+0.77%
    $NVS156.14+2.00%
    $JAZZ254.87+1.78%
    $ALLO1.8200-2.15%
    $GSK50.74-0.04%
    $SNY43.36-0.98%